960 related articles for article (PubMed ID: 26670617)
1. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
2. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
[TBL] [Abstract][Full Text] [Related]
4. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
6. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
[TBL] [Abstract][Full Text] [Related]
7. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
8. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
9. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
11. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
[TBL] [Abstract][Full Text] [Related]
13. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Wang WC; Dwan K
Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
[TBL] [Abstract][Full Text] [Related]
17. Transcranial Doppler velocity and brain MRI/MRA changes in children with sickle cell anemia on chronic transfusions to prevent primary stroke.
Sheehan VA; Hansbury EN; Smeltzer MP; Fortner G; McCarville MB; Aygun B
Pediatr Blood Cancer; 2013 Sep; 60(9):1499-502. PubMed ID: 23625812
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
20. Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia.
Bernaudin F; Verlhac S; Peffault de Latour R; Dalle JH; Brousse V; Petras E; Thuret I; Paillard C; Neven B; Galambrun C; Divialle-Doumdo L; Pondarré C; Guitton C; Missud F; Runel C; Jubert C; Elana G; Ducros-Miralles E; Drain E; Taïeb O; Arnaud C; Kamdem A; Malric A; Elmaleh-Bergès M; Vasile M; Leveillé E; Socié G; Chevret S;
JAMA; 2019 Jan; 321(3):266-276. PubMed ID: 30667500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
